Home About MEB Organisation Organisation structure

print this page

pharmacotherapeutical groups

The Pharmacotherapeutical groups 1 to 4 are responsible for the assessment of allopathic medicines. They make clinical assessments, provide scientific recommendations and assess (reports of) adverse events after authorisation. They make proposals to the MEB for authorisation or acceptance of changes. They also handle regulatory aspects (monitoring the European and national procedures), process coordination, management support and inspection of product information texts.

Any questions about the progress of a case (term questions) can be asked via the contact form.

PT group 1 assesses the following (groups of) medicines:

  • Central nervous system
  • Eyes
  • Anaesthetics
  • Musculoskeletal system, excluding osteoporosis
  • Analgesics
  • Teeth
  • Skin

Head of PT group 1: Mr Ronald (R.B.) Jansen
Secretary telephone: +31 88 224 8125
 
PT group 2 assesses the following (groups of) medicines:

  • Cardiovascular system
  • Sexual organs and reproduction
  • Osteoporosis
  • Cardiovascular disorders (including diabetes and obesity)
  • Diagnostics
  • Radiopharmaceuticals

Head of PT group 2: Mr Fons (A.I.M.) Wesseling
Secretary telephone: +31 88 224 8313

PT group 3 assesses the following (groups of) medicines:

  • Oncology
  • Blood and hematopoietic organs
  • Immunomodulators (including transplant products)
  • Antiemetics
  • Gases
  • Respiratory organs and upper respiratory tract (including allergens)

Head of FP group 3: Mr Sipko (H.S.) Mülder
Secretary telephone: +31 88 224 8181

PT group 4 assesses the following (groups of) medicines:

  • Vaccines
  • Infectious diseases
  • Fluids for use in hospital
  • Endocrinology (including growth hormones and thyroid gland)
  • Vitamins and minerals
  • Gastrointestinal disorders
  • Storage diseases (including Fabry and Gaucher)
  • Bladder dysfunctions

Head of PT group 4: Bert Hiemstra
Secretary telephone: +31 88 224 8107

Go back »

Back